MBRX · XBRL financial data

Moleculin Biotech financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (MBRX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	0	0	0	0	0	0
Research and development	12,757	14,418	18,968	19,487	17,729	15,891
General and administrative	6,785	8,386	11,542	10,017	8,786	9,122
Total operating expenses	19,742	22,968	30,640	29,631	26,641	25,103
Operating income (loss)	(19,742)	(22,968)	(30,640)	(29,631)	(26,641)	(25,103)
Other income (expense)	28	40	40	48	43	(20)
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(17,355)	(15,894)	(29,025)	(29,769)	(21,763)	(33,560)
Earnings per share, basic USD per share	—	(0.59)	(1.01)	(15.07)	(6.32)	(28.42)
Weighted average shares, basic thousands of shares	—	26,876	28,604	1,976	3,443	1,185

† Share count changed about 1/13 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (MBRX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	15,173	70,903	43,145	23,550	4,278	8,878
Prepaid and other current assets	2,025	1,594	2,451	2,723	916	808
Total current assets	17,198	72,497	45,596	26,273	5,194	9,686
Property and equipment, net	483	338	275	272	159	78
Right-of-use asset	202	107	403	524	424	314
Total assets	29,031	84,090	57,422	38,217	16,925	22,126
Accounts payable	1,129	1,364	2,095	2,498	2,030	3,508
Accrued liabilities	1,791	2,258	2,724	4,317	3,329	3,346
Total current liabilities	2,920	3,622	4,819	6,815	5,359	6,854
Lease liability, non-current	159	63	335	474	358	222
Total liabilities	11,271	5,097	5,231	12,144	10,946	7,120
Accumulated deficit	(56,916)	(72,810)	(101,835)	(131,604)	(153,367)	(206,004)
Total stockholders' equity	17,760	78,993	52,191	26,073	5,979	15,006
Total liabilities and equity	29,031	84,090	57,422	38,217	16,925	22,126
Common shares outstanding (cover page) thousands of shares	28,444	28,578	28,628	2,228	14,000	5,336

† Share count changed about 1/13 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (MBRX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(17,355)	(15,894)	(29,025)	(29,769)	(21,763)	(33,560)
Stock-based compensation	1,680	2,373	2,275	1,984	1,726	1,664
Depreciation and amortization	200	164	130	127	126	90
Net cash from operating activities	(17,771)	(18,951)	(27,639)	(24,101)	(23,862)	(22,735)
Purchases of property and equipment	376	19	67	124	13	0
Net cash from investing activities	(374)	(19)	(67)	(124)	(13)	0
Proceeds from issuing common stock	22,561	74,684	0	—	—	—
Net cash from financing activities	22,549	74,724	(23)	4,651	4,635	27,284
Net change in cash	4,438	55,730	(27,758)	(19,595)	(19,272)	4,600

† Share count changed about 1/13 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Moleculin Biotech	7,262	0	(6,657)*	19.5M	1.1 quarters	Q2 FY26 10-QJun 30, 2026
GT Biopharma	4,960	not reported	(4,260)*	45.1M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
TherapeuticsMD	9,189	not reported	not reported	11.6M	—	Q2 FY26 10-QJun 30, 2026
Oncotelic Therapeutics	186	250	(92)*	457.5M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Biovie	8,977	not reported	(4,122)*	7.5M	2.2 quarters	Q4 FY26 10-KJun 30, 2026
Artelo Biosciences	4,198	not reported	(5,033)*	4.6M	0.8 quarters	Q2 FY26 10-QJun 30, 2026
Bioxytran	177	not reported	(350)*	114.7M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Talphera	742	not reported	(3,924)*	51.9M	4.4 quarters	Q2 FY26 10-QJun 30, 2026
Raphael Pharmaceutical	1	not reported	0*	20.2M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.